Alkem Laboratories Share Price Target 2026, 2027, 2028, 2029, 2030

Alkem Laboratories share price today

Alkem Laboratories (NSE: ALKEM) owns the Indian pharmacy shelf where it matters most: anti-infectives, led by Clavam and a brand stable that ranks among the country’s most prescribed, plus gastro flagship Pan. Roughly two-thirds of revenue is domestic branded generics — the good kind of pharma, where brands compound and nobody in New Jersey sets your price.

The other third was the problem: US generics dragged margins for years. That drag is fading, and recent profit growth has run well ahead of the five-year averages as the mix shifts home. At 27.6× with a 21% ROCE, the tension is whether domestic brands and an improving US mix can keep lifting earnings despite acute-therapy cyclicality.

The domestic engine, the US anchor

Alkem’s domestic franchise skews acute — antibiotics, cold-and-fever season, gastro — which means prescriptions swing with infection cycles rather than compounding like chronic therapy. The offset: brand strength so deep that doctors write “Clavam” as if it were the molecule. Chronic-share expansion (diabetes, cardiac) is the stated strategy, and the US business has been pruned toward profitability rather than volume.

Watch-items: seasonal acute demand (a weak infection season is a weak quarter), NLEM price-cap expansions, US pricing on the remaining exposure, and trade-generics competition in antibiotics.

The numbers

Financial snapshot — 5 August 2026

Metric	Value
Market cap	₹67,335 Cr
P/E (TTM)	27.6
EV/EBITDA	18.8
Operating margin	20.4%
ROE / ROCE	18.9% / 21.2%
Debt to equity	0.15
Sales CAGR (5y)	10.7%
Profit CAGR (5y)	9.4%
Promoter holding	49.7%
EPS (TTM)	₹202.9

Alkem Laboratories share price target 2026 to 2030

EPS base ₹202.9 (TTM). Bear: acute seasons disappoint and price caps widen — 6% growth, multiple at 18×. Base: domestic brands compound and the US stays repaired — 11% growth at 24×. Bull: chronic-share gains accelerate the mix — 15% growth at 30×.

From ₹5,608, the base case is ≈ +46% over four and a half years plus a ~1% yield. The bear case is −13% — branded-domestic pharma rarely gets destroyed, it gets repriced. The range below waits for one of those repricings.

Reasons to own Alkem (at the right price)

1. Anti-infectives leadership — among India’s most prescribed brand stables.
2. Two-thirds domestic branded mix: pricing power without US FDA roulette.
3. The US drag is fading — recent profit growth runs far ahead of the 5-year average.
4. 27.6× is a discount to branded-domestic peers with similar franchises.
5. Chronic-therapy expansion is upside optionality on an acute base.

The risks: acute portfolios are hostage to infection seasons, NLEM can cap a flagship’s price overnight, and ROE in the high teens trails the MNC pharma benchmarks.

What to weigh at the current price

Alkem’s valuation is most interesting when seasonal softness creates a discount without weakening the India franchise or the US-margin recovery.

FAQ

What is the Alkem Laboratories share price target for 2030? The table above sets out bear, base and bull scenarios for each year through 2030. These are valuation sensitivities, not promised prices.

What are Alkem’s biggest brands? Clavam (antibiotic), Pan/Pan-D (gastro), Taxim (antibiotic) — several rank among India’s top-selling pharmaceutical brands by prescription.

Why did Alkem’s five-year profit CAGR look weak? US generic price erosion consumed what the domestic business earned. As the US mix shrank and pricing stabilised, consolidated growth re-accelerated — the TTM tells that story.

When are Alkem’s next results? Check the results calendar and confirm the announced date in the relevant exchange filing.

---

This article is research and education, not personalised investment advice. We are not SEBI-registered advisers. Price targets are scenario arithmetic, not promises. Do your own research and consult a registered adviser before acting.